AU2013252771B2 - Methods of producing and using regulatory B-cells - Google Patents

Methods of producing and using regulatory B-cells Download PDF

Info

Publication number
AU2013252771B2
AU2013252771B2 AU2013252771A AU2013252771A AU2013252771B2 AU 2013252771 B2 AU2013252771 B2 AU 2013252771B2 AU 2013252771 A AU2013252771 A AU 2013252771A AU 2013252771 A AU2013252771 A AU 2013252771A AU 2013252771 B2 AU2013252771 B2 AU 2013252771B2
Authority
AU
Australia
Prior art keywords
cells
protein
isolated
mammal
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013252771A
Other languages
English (en)
Other versions
AU2013252771A1 (en
Inventor
Charles Emeka Egwuagu
Ren-xi WANG
Cheng-rong YU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2013252771A1 publication Critical patent/AU2013252771A1/en
Application granted granted Critical
Publication of AU2013252771B2 publication Critical patent/AU2013252771B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2327—Interleukin-27 (IL-27)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2335—Interleukin-35 (IL-35)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
AU2013252771A 2012-04-25 2013-04-11 Methods of producing and using regulatory B-cells Active AU2013252771B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261637915P 2012-04-25 2012-04-25
US61/637,915 2012-04-25
PCT/US2013/036175 WO2013162905A1 (en) 2012-04-25 2013-04-11 Methods of producing and using regulatory b-cells

Publications (2)

Publication Number Publication Date
AU2013252771A1 AU2013252771A1 (en) 2014-10-30
AU2013252771B2 true AU2013252771B2 (en) 2017-06-08

Family

ID=48183014

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013252771A Active AU2013252771B2 (en) 2012-04-25 2013-04-11 Methods of producing and using regulatory B-cells

Country Status (6)

Country Link
US (1) US9629897B2 (https=)
EP (1) EP2841562B1 (https=)
JP (1) JP6258922B2 (https=)
AU (1) AU2013252771B2 (https=)
CA (1) CA2871499C (https=)
WO (1) WO2013162905A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526520A (ja) * 2012-08-31 2015-09-10 プリンシピア バイオファーマ インコーポレイテッド Ｉｔｋ阻害剤としてのベンズイミダゾール誘導体
WO2018013897A1 (en) * 2016-07-15 2018-01-18 Board Of Regents, The University Of Texas System Regulatory b cells and uses thereof
GB201707238D0 (en) 2017-05-05 2017-06-21 Univ Oxford Innovation Ltd Composition
CA3068286A1 (en) * 2017-06-22 2018-12-27 Board Of Regents, The University Of Texas System Methods for producing regulatory immune cells and uses thereof
CA3107687A1 (en) * 2018-02-26 2019-08-29 Claudia Zylberberg Immune cell activation
JP2022526843A (ja) 2019-04-12 2022-05-26 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 制御性ｂ細胞の産生方法およびその使用
WO2020257408A1 (en) 2019-06-18 2020-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interleukin-27 producing b-cells and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110135666A1 (en) * 2008-04-25 2011-06-09 Duke University Regulatory b cells and their uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090400A1 (en) * 2004-03-18 2005-09-29 The University Court Of The University Of Glasgow Immunosuppressive cytokine
BRPI0610824A8 (pt) 2005-05-16 2017-04-04 Prometic Pharma Smt Ltd Compostos derivados de purina, uso dos mesmos e composição contendo os referidos compostos
US8592364B2 (en) * 2010-02-11 2013-11-26 Ecole Polytechnique Federale de Lausanne (“EPFL”) CCR7 ligand delivery and co-delivery in immunotherapy
WO2012082771A1 (en) * 2010-12-13 2012-06-21 The Board Of Trustees Of The Leland Stanford Junior University Cardiac glycosides for treating autoimmune disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110135666A1 (en) * 2008-04-25 2011-06-09 Duke University Regulatory b cells and their uses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Collison LW et al, "The inhibitory cytokine IL-35 contributes to regulatory T-cell function", Nature, 2007, 450(7169):566-569 *
Fujita H et al, "Mechanisms of allergen-specific immunotherapy", Clinical and Translational Allergy, 2012, 2(1):2 *
Kochetkova I et al, "IL-35 Stimulation of CD39+ Regulatory T Cells Confers Protection againts Collagen II-Induced Arthritis via the Production of IL-10", The Journal of Immunology, 2010, 184(12):7144-7153 *

Also Published As

Publication number Publication date
US9629897B2 (en) 2017-04-25
WO2013162905A8 (en) 2014-01-23
JP2015516156A (ja) 2015-06-11
EP2841562B1 (en) 2020-06-03
WO2013162905A1 (en) 2013-10-31
US20150110737A1 (en) 2015-04-23
CA2871499A1 (en) 2013-10-31
CA2871499C (en) 2021-08-17
EP2841562A1 (en) 2015-03-04
JP6258922B2 (ja) 2018-01-10
AU2013252771A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
AU2013252771B2 (en) Methods of producing and using regulatory B-cells
Liu et al. Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression
RU2716716C2 (ru) Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии
Camporeale et al. IL-6, IL-17 and STAT3: a holy trinity in auto-immunity?
US20250270272A1 (en) Methods of treating multiple sclerosis using autologous t cells
RU2756276C2 (ru) Способы иммунотерапии
JP2025111489A (ja) Ｉｎｔｅｒｌｅｕｋｉｎ－２７産生ｂ細胞及びその使用
KR102569644B1 (ko) Gdf15를 유효성분으로 함유하는 면역질환의 예방 및 치료용 조성물
Lamba Comprehensive exploration of T follicular regulatory cells in autoimmunity
JP6739106B2 (ja) 自己免疫疾患の治療用ペプチド断片
WO2024235355A1 (zh) 一种嵌合抗原受体、重组免疫细胞及用途
Westhovens et al. Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment
Lebre et al. Characterization of BDCA1 and BDCA4 dendritic cell subsets in rheumatoid arthritis patients
Zgaga-Griesz et al. Aberrant expression of the co-chaperone HDJ2 in rheumatoid arthritis
Yurovsky Cross-talk between TRAIL and TGF-β in regulation of collagen production in scleroderma lung disease
HK40015966A (en) Methods of treating multiple sclerosis using autologous t cells
De Rycke et al. Serum MRP8/MRP14 as a biomarker for inflammation in autoimmune arthritis
Hoffman et al. False positivity of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus
Akhtar Cytokine profiles and immunomodulation of T cells in immune-mediated ocular diseases
Korotkova et al. Effects of anti-rheumatic treatments on expression of microsomal prostaglandin E synthase-1 in rheumatoid arthritis synovium
Hartwell Transcriptional and post-transcriptional aspects of the aberrant expression of IL-1 in lupus-prone mice
Ambrozic et al. Prothrombin fragment F1+ 2 in patients with antiphospholipid antibodies
Jaen et al. Effect of an empty plasmid containing CpG on dendritic cells: in vitro steady state of stimulation, in vivo prevention of collagen-induced arthritis
Morgan et al. CD25+ regulatory T cells can be used therapeutically in collagen-induced arthritis
Ambrozic et al. Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)